Kenneth Steadman

Plex Pharmaceuticals (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.6kcitations57works0.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Nuclear Structure and Function(13), GaN-based semiconductor devices and materials(9), Semiconductor materials and devices(9), Drug Transport and Resistance Mechanisms(7), RNA Research and Splicing(7)

Publications57 total

Abstract 1653: Preclinical characterization of PLX-61639, a potent and orally bioavailable SMARCA2-selective monovalent direct degrader
Cancer Research·2025
Abstract 404: Mechanistic characterization of selective monovalent direct degraders of SMARCA2
Cancer Research·2025
Supplementary Table S4 from Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
2024Open Access
Supplementary Table S3 from Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
2024Open Access
Supplementary Table S1 from Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
2024Open Access
Supplemental Figure S1 from Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
2024Open Access
Supplementary Data from Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
2024Open Access
Supplemental Figure S2 from Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
2024Open Access
Data from Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
2024Open Access
Supplementary Figure S3 from Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
2024Open Access
Supplementary Table S2 from Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
2024Open Access
Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
Molecular Cancer Therapeutics·2024· 11 citedOpen Access
Autonomous action and cooperativity between the ONECUT2 transcription factor and its 3′ untranslated region
Frontiers in Cell and Developmental Biology·2023· 4 citedOpen Access
Movie S1 from Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential
2023Open Access
Data from Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential
2023Open Access
Movie S1 from Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential
2023Open Access
Supplementary Figure legends from Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential
2023Open Access
Movie S2 from Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential
2023Open Access
Supplementary Figure legends from Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential
2023Open Access
Movie S3 from Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Susan E. Bates(13), Sungyong You(13), Dolores Di Vizio(12), Beatrice S. Knudsen(12), Mirja Rotinen(11), Mariana Reis-Sobreiro(11), Chia-Yi Chu(11), Leland W.K. Chung(11), Samantha Morley(11), Hisashi Tanaka(11), Jie‐Fu Chen(10), Tatiana Novitskaya(10), Navjot Kaur Gill(10), Adel Eskaros(10), Hsian‐Rong Tseng(10), Amy C. Rowat(10), Edwin M. Posadas(10), Andries Zijlstra(10), Michael R. Freeman(10), Julia I. Toth(10)